107 related articles for article (PubMed ID: 26631427)
1. Molecular Taxonomy and Tumourigenesis of Colorectal Cancer.
Biswas S; Holyoake D; Maughan TS
Clin Oncol (R Coll Radiol); 2016 Feb; 28(2):73-82. PubMed ID: 26631427
[TBL] [Abstract][Full Text] [Related]
2. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
[TBL] [Abstract][Full Text] [Related]
3. Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer.
Włodarczyk M; Włodarczyk J; Siwiński P; Sobolewska-Włodarczyk A; Fichna J
Curr Drug Targets; 2018; 19(15):1731-1737. PubMed ID: 30073926
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.
Wielandt AM; Hurtado C; Moreno C M; Villarroel C; Castro M; Estay M; Simian D; Martinez M; Vial MT; Kronberg U; López-Köstner F
Tumour Biol; 2020 Jul; 42(7):1010428320938492. PubMed ID: 32635826
[TBL] [Abstract][Full Text] [Related]
5. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
[No Abstract] [Full Text] [Related]
6. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
7. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
8. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
Segelov E; Waring P; Desai J; Wilson K; Gebski V; Thavaneswaran S; Elez E; Underhill C; Pavlakis N; Chantrill L; Nott L; Jefford M; Khasraw M; Day F; Wasan H; Ciardiello F; Karapetis C; Joubert W; van Hazel G; Haydon A; Price T; Tejpar S; Tebbutt N; Shapiro J
BMC Cancer; 2016 May; 16():339. PubMed ID: 27246726
[TBL] [Abstract][Full Text] [Related]
9. Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorectal liver metastasis.
Søreide K; Watson MM; Lea D; Nordgård O; Søreide JA; Hagland HR;
J Transl Med; 2016 Jun; 14(1):192. PubMed ID: 27357108
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathological classification of colorectal cancer.
Müller MF; Ibrahim AE; Arends MJ
Virchows Arch; 2016 Aug; 469(2):125-34. PubMed ID: 27325016
[TBL] [Abstract][Full Text] [Related]
11. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
12. Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment.
Dienstmann R; Tabernero J
Cancer J; 2016; 22(3):149-55. PubMed ID: 27341591
[TBL] [Abstract][Full Text] [Related]
13. External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS.
Alwers E; Bläker H; Walter V; Jansen L; Kloor M; Arnold A; Sieber-Frank J; Herpel E; Tagscherer KE; Roth W; Chang-Claude J; Brenner H; Hoffmeister M
BMC Cancer; 2019 Jul; 19(1):681. PubMed ID: 31296182
[TBL] [Abstract][Full Text] [Related]
14. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
[TBL] [Abstract][Full Text] [Related]
15. Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer.
Inoue M; Takahashi S; Soeda H; Shimodaira H; Watanabe M; Miura K; Sasaki I; Kato S; Ishioka C
Int J Clin Oncol; 2015 Dec; 20(6):1147-55. PubMed ID: 25990448
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers in Colorectal Cancer.
Yiu AJ; Yiu CY
Anticancer Res; 2016 Mar; 36(3):1093-102. PubMed ID: 26977004
[TBL] [Abstract][Full Text] [Related]
17. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
18. [The RAS paradox of the EGFR-targeted therapy in colorectal cancer].
Tímár J; Láng I
Magy Onkol; 2008 Jun; 52(2):185-91. PubMed ID: 18640895
[TBL] [Abstract][Full Text] [Related]
19. Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer.
Dienstmann R; Salazar R; Tabernero J
Am Soc Clin Oncol Educ Book; 2018 May; 38():231-238. PubMed ID: 30231342
[TBL] [Abstract][Full Text] [Related]
20. Simple classifiers for molecular subtypes of colorectal cancer.
Kim WG; Kim JY; Park DY
Arab J Gastroenterol; 2017 Dec; 18(4):191-200. PubMed ID: 29241727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
